BEIJING AND BRIDGEWATER, N.J.

Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, single, ascending dose clinical study in the U.S. for the company’s investigational drug, GZR18. GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) […]

thaipr.net

11 มี.ค. 65

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company’s compound, GZR18, to improve the management of type 2 diabetes mellitus. The investigational compound, GZR18, is […]

thaipr.net

8 ธ.ค. 64

Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic. The two studies were conducted separately in subjects with type 1 (n=576) and type […]

thaipr.net

15 ต.ค. 64

Gan & Lee Pharmaceuticals to present recent data at the 57th Annual European Association for the Study of Diabetes Meeting

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five recent abstracts which will be featured as short oral discussions at the 57th Annual European Association for the Study of Diabetes (EASD) Meeting. The meeting will be held virtually from September 27th – […]

thaipr.net

9 ก.ย. 64

Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma. Glioma is a broad term describing neuroepithelial tumors […]

thaipr.net

8 เม.ย. 64

Gan & Lee Announces New Partnership with International Diabetes Federation

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, has announced a collaborative partnership with the International Diabetes Federation (IDF) that aims to support their global efforts of promoting diabetes care and prevention worldwide. This collaboration will allow opportunities to support future initiatives such as medical […]

thaipr.net

23 ก.พ. 64

Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma. GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that Gan & Lee […]

thaipr.net

5 ก.พ. 64

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.